Search Results

OrthoTrophix, Inc. announced that the Company will present the latest clinical data and registration plan of TPX-100 in knee osteoarthritis patients at BIO 2022.

OrthoTrophix, Inc., a privately held biopharmaceutical company, announced that the Company and its collaborators present clinical data strongly supporting joint bone shape change as part of a surrogate marker predictive of joint replacement in knee osteoarthritis patients.

OrthoTrophix, Inc., a privately held biopharmaceutical company, announced that the Company and its collaborators have published a new research article presenting clinical data demonstrating disease modification in knee osteoarthritis patients treated with TPX-100, the Company’s leading candidate for a Disease Modifying Osteoarthritis Drug.

OrthoTrophix, Inc. announced that the Company has demonstrated evidence for disease modification in knee osteoarthritis in patients treated with TPX-100, the Company’s leading candidate for a Disease Modifying Osteoarthritis Drug.

OrthoTrophix, Inc. announced that the Company has demonstrated more evidence for disease modification in knee osteoarthritis patients treated with TPX-100, the Company’s leading candidate for a Disease Modifying Osteoarthritis Drug.

OrthoTrophix, a privately held biopharmaceutical company, announced today that the company and its collaborators presented the Phase 2 clinical study data of TPX-100 demonstrating structural improvement of knee cartilage associated with robust knee function improvement in knee osteoarthritis (OA) patients at the American College of Rheumatology (ACR/ARHP) Annual Meeting in Chicago, IL

OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the company and its collaborators will present a late breaking abstract entitled, “Intra-Articular TPX-100 in Knee Osteoarthritis: Robust Functional Response at 6 and 12 Months is Associated with Increased Tibiofemoral Cartilage Thickness

Demonstrating Significant Correlation between Knee Function Improvement and Cartilage Thickness Increase/Stabilization after TPX-100

OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the company plans to report long-term clinical benefits in mild to severe knee osteoarthritis (OA) patients who were treated with TPX-100 at the 2018 OARSI annual meeting (Liverpool, U.K., 26-29 April 2018).

Based on this double-blinded, placebo-controlled, multi-center study, data are presented from 93 subjects with bilateral knee OA who received 4 weekly doses of TPX-100 by intra-articular administration in one knee and identical placebo injections in the other, with at least one follow-up evaluation at 6 and 12 months.